期刊文献+

人表皮生长因子受体结构域蛋白的原核表达、纯化及活性检测 被引量:1

Prokaryotic Expression,Purification and Activity Detection of the Extracellular and Intracellular Domains of Human EGFR Subunit
下载PDF
导出
摘要 目的:构建人表皮生长因子受体(EGFR)胞外结构域(ED)和胞内激酶结构域(PKD)的原核表达载体,获得纯化的GST-EGFR-ED和GST-EGFR-PKD融合蛋白,并检测其活性。方法:用PCR方法从乳腺文库中扩增EGFR的ED和PKD基因编码序列,将其正确插入p GEX-KG载体,重组质粒转化大肠杆菌Rossate表达后,用GST-Sepharose4B珠子纯化融合蛋白。结果:构建得到GST-EGFR-ED和GST-EGFR-PKD的原核表达载体,双酶切鉴定得到与预期片段大小相符的外源基因插入片段,经测序与目的序列完全一致;在Rossate菌中诱导表达出与预期位置相符的目的蛋白,经Western印迹检测,融合蛋白成功表达;纯化得到融合蛋白GST-EGFR-ED和GST-EGFR-PKD。结论:克隆了GST-EGFR-ED和GST-EGFR-PKD基因,并获得了活性良好的GST-EGFR-ED和GST-EGF-PKD融合蛋白,为研究EGFR在肿瘤中的作用奠定了实验基础。 Objective: To clone prokaryotic expression vectors of extracellular domain(ED) and protein kinase do- main(PKD) of human epithelial growth factor receptor(EGFR), and express and purify the fusion proteins of GST- EGFR-ED and GST-EGFR-PKD, and identify their functions preliminarily. Methods: ED and PKD coding re- gions of EGFR were amplified from human mammary cDNA library by PCR and cloned into the prokaryotic expres- sion vector pGEX-KG. The fusion proteins of GST-EGFR-ED and GST-EGFR-PKD were expressed in E.coli Ros- sate and purified by GST-Sepharose 4B beads. The interactions of the proteins with memo were identified by GST pull-down assay. Results: GST-EGFR-ED and GST-EGFR-PKD recombinant plasmids were successfully obtained by double digestion identification. The inserted fragments were confirmed correct by sequencing. The fusion pro- teins were successfully induced and identified by Western blot analysis. Conclusion: GST-EGFR-ED and GST- EGFR-PKD were successfully cloned and purified.
出处 《生物技术通讯》 CAS 2015年第5期615-618,共4页 Letters in Biotechnology
基金 国家自然科学基金(81472589 31100604) 北京市自然科学基金(7132155) 北京市科技新星计划(Z141102001814055) 军事医学科学院创新基金转化医学项目(ZHYX003)
关键词 人表皮生长因子受体 胞外结构域 胞内激酶结构域 原核表达 纯化 human epithelial growth factor receptor extracellular domain protein kinase domain prokaryotic ex-pression purification
  • 相关文献

参考文献15

  • 1Harari P M, Huang S M. Head and neck cancer as a clini- cal model for molecular targeting of therapy: combining EG- FR blockade with radiation[J]. Int J Rediat Oncol Bid Phys, 2001,49(2):427-433.
  • 2Perez-Soler R. HER1/EGFR targeting: refining the strategy[J]. Oncologist, 2004,9(1):58-67.
  • 3Yarden Y, Sliwkoski M X. Untangling the ErbB signaling network[J]. Nat Rev Mol Cell Biol, 2001,2(2):127-137.
  • 4Ritter C A, Arteaga C L. The epidermal growth factor recep- tor-tyrosine kinase: a promising therapeutic target in solid tu- mors[J]. Semin Oncol, 2003,30(Suppl 1):3-11.
  • 5Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinas- es and cancer[J]. Biochem Biophys Res Commun, 2004,319(1): 1-11.
  • 6Stonecypher M S, Chaudhury A R, Byer S J, et al. Neuregu- lin growth factors and their ErhB receptors form apotential signaling network for schwannoma tumorigenesis[J]. J Neuro- pathol Exp Neurol, 2006,65(2):162-175.
  • 7Mendelsohn J, Baselga J. Status of epidermal growth factor re- ceptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003,21(14):2787-2799.
  • 8Castillo L, Etienne-Grimaldi M C, Fischel J L, et al. Pharma- cological background of EGFR targeting[J]. Ann Oncol, 2004, 15(7):1007-1012.
  • 9Arteaqa C L. Epidermal growth factor receptor dependence in human tumors: more than just expression[J]? Oncologist, 2002, 7(Suppl 4):31-39.
  • 10Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [J]. N Engl J Med, 2008,358(11):1160-1174.

二级参考文献15

  • 1Ying Dong,Bing Qi,Xiao-Ying Feng,Chun-Meng Jiang.Meta-analysis of Barrett's esophagus in China[J].World Journal of Gastroenterology,2013,19(46):8770-8779. 被引量:6
  • 2司富春,陈玉龙,徐晓宇,王庆其.古代中医文献对食管癌的认识[J].河南中医,2005,25(6):77-79. 被引量:22
  • 3Karapetis CS, Khambata-Ford $,Jonker DJ,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008,359 : 1757-1765.
  • 4Zolota V, Batistatou A, Tsamandas AC, et al expression of TGF-betal, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas:a clinicopathologic study. Int J Gastrointest Canc- er,2002,32:83-89.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American society of clin- ical oncology/college of American pathologists guideline recommenda- tions for human epidermal growth factorreceptor 2 testing in breast cancer. Arch Pathol Lab Med,2007,131:18-43.
  • 6Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer, 1993, 71: 2454-2460.
  • 7Park DI, Kang MS, Oh SJ, et al. HER-2/neu overexpression is an in- dependent prognostic factor in colorectal cancer. Int J Colorectal Dis, 2007,22:491-497.
  • 8PadiUa D, Cubo T, ViUarejo P, et al. Molecular profile of node-nega- tive colorectal cancer of poor prognosis using immunohistochemical de- termination of p53 ,ki67 ,VEGF and metalloproteinase-9. Rev Esp En- fern Dig,2007,99:424-425.
  • 9Bura M, Seiverth S, Vladika I, et al. Possible prognostic significance of p53 and Ki67 in inverted sinonasal papilkma. Coil Antropol, 2007, 31:545-549.
  • 10Forones NM, Oshima C, Nanogaki S, et al. Determination of prolifera- tive activity using ki67 and expression of p53 in eoloreetal cancer. Arq Gastroenterol, 1999,36 : 122-126.

共引文献12

同被引文献6

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部